Q&A: Owkin’s five-year Sanofi deal bets on ‘purpose-built’ AI agents
Summary
Owkin has signed a five-year license agreement with Sanofi for its K Pro platform and is positioning it as a purpose-built AI agent system for pharma work. The initial scope covers competitive intelligence and decision support, and the deal does not yet include Owkin’s lab-in-the-loop validation. Sanofi can connect its existing AI stack to K Pro through modular integrations, while its data stays internal under Owkin’s privacy safeguards. The partnership aims to deliver three specialist agents and increase Sanofi’s use of K Pro over the next few years.
Classifications
industries
HealthTech
applications
Data Management
AskAI Classifications
Labels
Biotechnology
Artificial Intelligence
Healthcare Software
Linked Companies
Owkin, Inc
$50M to $100M